Institute for Clinical and Economic Review to Assess Treatments for Myasthenia Gravis
March 16, 2021
March 16, 2021
BOSTON, Massachusetts, March 16 (TNSRes) -- The Institute for Clinical and Economic Review issued the following announcement on March 15, 2021:
The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of efgartigimod (argenx, Halozyme Therapeutics, and Zai Lab) and eculizumab (Soliris(R), Alexion Pharmaceuticals, Inc.) for the treatment of myasthenia gravis. An FDA decision on efgartigimod is expected . . .
The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of efgartigimod (argenx, Halozyme Therapeutics, and Zai Lab) and eculizumab (Soliris(R), Alexion Pharmaceuticals, Inc.) for the treatment of myasthenia gravis. An FDA decision on efgartigimod is expected . . .